Search - tctmd.com

Displaying 181 - 200 of 343

Sort: Relevancy | Date

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

L.A. McKeown

June 17, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

Kawasaki Link to COVID-19 in Kids Probed as UK, New York Issue Alerts

Shelley Wood

May 06, 2020

News Daily News

RV Strain a Prognostic Marker for Mortality in COVID-19

Caitlin E. Cox

May 04, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Michael O'Riordan

January 16, 2020

News Daily News

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

Yael L. Maxwell

December 11, 2019

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Most Stable Angina Patients Not Taking First-line Meds

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Kawasaki Link to COVID-19 in Kids Probed as UK, New York Issue Alerts

RV Strain a Prognostic Marker for Mortality in COVID-19

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Statins Started in Kids With FH Provide Benefits in Adulthood

Recurrent Events Common Among Young Patients With CAD

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content